Patents Examined by John L. LaGuyader
  • Patent number: 6001654
    Abstract: Method for producing a population of mammalian neurons and/or smooth muscle cells comprising contacting at least one mammalian neural stem cell with a culture medium containing one or more growth factors from the TGF-.beta. super family and detecting the differentiation of stem cell to a population of neurons or smooth muscle cells.
    Type: Grant
    Filed: April 25, 1997
    Date of Patent: December 14, 1999
    Assignee: California Institute of Technology
    Inventors: David J. Anderson, Nirao M. Shah
  • Patent number: 5994109
    Abstract: Nucleic acid transporter systems for delivery of nucleic acid to a cell. The nucleic acid transporter includes a binding complex. The binding complex contains a binding molecule which non-covalently binds to the nucleic acid and covalently links to a surface ligand, nuclear ligand and/or a lysis agent. These may be linked to the binding molecule by spacers.
    Type: Grant
    Filed: June 3, 1995
    Date of Patent: November 30, 1999
    Assignee: Baylor College of Medicine
    Inventors: Savio L. C. Woo, Louis C. Smith, Richard J. Cristiano, Stephen Gottchalk, Jim Sparrow
  • Patent number: 5985668
    Abstract: The invention relates to sucrose isomerases, to DNA sequences coding therefor, and to novel processes for producing noncariogenic sugars.
    Type: Grant
    Filed: June 27, 1996
    Date of Patent: November 16, 1999
    Assignee: Sudzucker Aktiengesellschaft Mannheim/Ochsenfurt
    Inventors: Ralf Mattes, Kathrin Klein, Sabine Stegmaier
  • Patent number: 5891724
    Abstract: A novel protein associated with multidrug resistance in living cells and capable of conferring multidrug resistance on a cell is disclosed. Nucleic acids encoding the novel multidrug resistance protein are also disclosed. Transformant cell lines which express the nucleic acid encoding the novel protein are also disclosed. Antibodies which bind the novel multidrug resistance protein are also disclosed. Diagnostic and treatment methods using the novel proteins, nucleic acids, antibodies and cell lines of the invention are also encompassed by the invention.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: April 6, 1999
    Assignee: Queen's University at Kingston
    Inventors: Roger G. Deeley, Susan P. C. Cole
  • Patent number: 5863774
    Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 26, 1999
    Assignees: The General Hospital Corporation, President and Fellows of Harvard College
    Inventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman
  • Patent number: 5516693
    Abstract: The instant invention is drawn to plasmid p1BN10 harbored in E. coli DSM 4020 and coding for a Bacillus thuringiensis endotoxin (Bt8 toxin) fused in frame to the neo gene of pBR322.
    Type: Grant
    Filed: March 4, 1987
    Date of Patent: May 14, 1996
    Assignee: Board of Trustees operating Michigan State University
    Inventors: Mark A. Vaeck, Wipa Chungjatupornchai, Lee McIntosh